ADD/ADHD

KnoWEwell Appoints Drs. Patterson and Stenzler to Operations Posts

Retrieved on: 
Wednesday, December 21, 2022

FAR HILLS, N.J. , Dec. 21, 2022 /PRNewswire/ -- KnoWEwell P.B.C., the Regenerative Whole Health benefits and services company, announced the appointment of Jaquel Patterson, ND, MBA, IFMCP, as Co-Chief Operating Officer, and Brian Stenzler, MS, DC, as Vice President of Operations.

Key Points: 
  • FAR HILLS, N.J. , Dec. 21, 2022 /PRNewswire/ -- KnoWEwell P.B.C., the Regenerative Whole Health benefits and services company, announced the appointment of Jaquel Patterson, ND, MBA, IFMCP, as Co-Chief Operating Officer, and Brian Stenzler, MS, DC, as Vice President of Operations.
  • "KnoWEwell is thrilled to have leaders of the caliber of Dr. Patterson and Dr. Stenzler join the company to oversee operations, foster collaborative partnerships, and enhance KnoWEwell benefits and services," stated Kimberly Whittle, KnoWEwell's Founder and CEO.
  • Dr. Patterson is a nationally recognized naturopathic physician, business-success coach, speaker, Forbes contributor, and bestselling author of Naturalpreneurs: Building Your Successful and Scalable Integrative Medical Practice.
  • Dr. Stenzler is a sought-after speaker, has been featured on television and radio, and is a bestselling author.

ICCTA Adopts Neurodiversity Inclusion Statement at Board of Representatives Meeting

Retrieved on: 
Tuesday, November 22, 2022

We believe that, when neurodivergent people are understood, valued, and empowered, we all stand to benefit from their important and unique contributions.

Key Points: 
  • We believe that, when neurodivergent people are understood, valued, and empowered, we all stand to benefit from their important and unique contributions.
  • This resolution represents our commitment to promoting an authentically inclusive learning environment in alignment with this ideal."
  • As ICCTA President, Dr. Dunne's vision includes a focus on neurodiversity inclusion, future of work, and closer industry partnerships with the community college system.
  • As a leading voice in the neurodiversity movement, Dr. Dunne regularly speaks on these topics, including as a keynote speaker at the Stanford Neurodiversity Summit and as an invited speaker at The Atlantic Festival, which included neurodiversity as part of its Diversity, Equity, and Inclusion focus.

NutraLife Biosciences Launches a Clinically Tested Focus Stimulant Under a Master Distribution Agreement

Retrieved on: 
Thursday, October 27, 2022

(WFFSP) for the co-marketing and distribution of Addy, a focus stimulant product designed to enhance sustained attention and support better mental clarity.

Key Points: 
  • (WFFSP) for the co-marketing and distribution of Addy, a focus stimulant product designed to enhance sustained attention and support better mental clarity.
  • NutraLife Biosciences is making the Addy product available online at www.buyaddy.com/ and will begin distributing the products through various retail, online, and outlets nationwide.
  • NutraLife BioSciences, Inc. operates a multifaceted life sciences and lifestyle health and wellness manufacturing company.
  • This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the Company).

Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022

Retrieved on: 
Thursday, October 13, 2022

Biomerica has over 100 issued and pending patents on the InFoods Technology in many countries pertaining to multiple diseases.

Key Points: 
  • Biomerica has over 100 issued and pending patents on the InFoods Technology in many countries pertaining to multiple diseases.
  • Zackary Irani, Biomerica CEO commented, "We are focusing on significant near-term revenue opportunities in three key areas.
  • Biomerica primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
  • Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica.

Innovation DuPage Launches New Program for Neurodivergent Founders in Partnership With the Autism Angels Group

Retrieved on: 
Friday, September 16, 2022

GLEN ELLYN, Ill., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Business incubator and accelerator Innovation DuPage (ID) has partnered with Autism Angels Group (AAG) to provide ongoing support to neurodivergent entrepreneurs.

Key Points: 
  • GLEN ELLYN, Ill., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Business incubator and accelerator Innovation DuPage (ID) has partnered with Autism Angels Group (AAG) to provide ongoing support to neurodivergent entrepreneurs.
  • NDEP celebrates and invests in the success of startups and small companies that have neurodivergent leaders in C-Suite roles (e.g., CEO, CFO, Directors, founders, or cofounders).
  • The three organizations have come together to fund, offer, and host NDEP to drive success among neurodivergent entrepreneurs, founders, and business leaders.
  • "NDEP is about showing how cognitive differences can drive organizational success in new business ventures," stated Joe Cassidy, Innovation DuPage President and Chair.

BioLife Sciences Inc. Expands Product Offerings in the Orthomolecular Medicine and Natural Health Markets with a Focus on Hemp Products

Retrieved on: 
Wednesday, August 24, 2022

HENDERSON, Nev., Aug. 24, 2022 (GLOBE NEWSWIRE) -- BioLife Sciences Inc. (BioLife or the Company) (OTC: BLFE) announced today that it will be expanding the scope of its orthomolecular medicine and natural health products division, with a specific focus on disruptive hemp products.

Key Points: 
  • HENDERSON, Nev., Aug. 24, 2022 (GLOBE NEWSWIRE) -- BioLife Sciences Inc. (BioLife or the Company) (OTC: BLFE) announced today that it will be expanding the scope of its orthomolecular medicine and natural health products division, with a specific focus on disruptive hemp products.
  • BioLife will be focused on throat and cough syrups infused with cannabinoids, cannabinoid-infused teas and CBD Energy Shots.
  • Additionally, the Company will focus on pet products infused with cannabinoids which offer wellness support for cats and dogs.
  • BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption.

Moleculera Labs and General Genomics Form Strategic Alliance to Utilize Proprietary AI to Provide Personalized Medicine for Autoimmune Neuropsychiatric Disorders

Retrieved on: 
Tuesday, July 26, 2022

OKLAHOMA CITY, July 26, 2022 /PRNewswire/ -- Moleculera Labs, Inc. (Moleculera) and General Genomics, Inc. (GGI) announce the formation of a strategic alliance between the two companies.

Key Points: 
  • OKLAHOMA CITY, July 26, 2022 /PRNewswire/ -- Moleculera Labs, Inc. (Moleculera) and General Genomics, Inc. (GGI) announce the formation of a strategic alliance between the two companies.
  • Moleculera Labs, Inc. is a precision medicine company focused on identifying the underlying root of neurologic, psychiatric, and behavioral disorders.
  • General Genomics, Inc. is a cutting-edge bioinformatics, AI and machine learning organization founded by former General Electric (GE) and Baker Hughes AI engineers.
  • Moleculera Labs is a precision medicine company focused on understanding the biological roots and testing for autoimmune neuropsychiatric disorders.

Amy Schumer Joins the Board of Directors of the Hyperemesis Education and Research (HER) Foundation

Retrieved on: 
Thursday, May 12, 2022

Schumer experienced Hyperemesis Gravidarum while pregnant with her son, Gene, and documented the journey with husband, Chris Fischer, in her docuseries, Expecting Amy.

Key Points: 
  • Schumer experienced Hyperemesis Gravidarum while pregnant with her son, Gene, and documented the journey with husband, Chris Fischer, in her docuseries, Expecting Amy.
  • Executive Director and co-founder, Kimber MacGibbon, a Registered Nurse who appears in Expecting Amy , is pleased to welcome Schumer to the Board.
  • Schumer will join other sector leaders on the HER Foundation's Board of Directors to guide operations and programs which include crisis support services, patient and provider education, breakthrough research, awareness, and advocacy.
  • The Hyperemesis Education and Research (HER) Foundation is a 501(c)3 nonprofit that provides support, groundbreaking research, advocacy, and education on hyperemesis gravidarum (HG), a debilitating disease of pregnancy.

First Light Recovery Announces New In-Network Insurances

Retrieved on: 
Monday, April 11, 2022

SAN JUAN CAPISTRANO, Calif., April 11, 2022 /PRNewswire/ -- First Light Recovery announced new in-network agreements with Anthem BlueCross, Kaiser Permanente, Magellan, HMC Healthworks, First Health, Multiplan and the latest, United Healthcare.

Key Points: 
  • SAN JUAN CAPISTRANO, Calif., April 11, 2022 /PRNewswire/ -- First Light Recovery announced new in-network agreements with Anthem BlueCross, Kaiser Permanente, Magellan, HMC Healthworks, First Health, Multiplan and the latest, United Healthcare.
  • First Light Recovery offers a variety of treatment options for those struggling with mental health disorders.
  • Individuals who are interested in the care provided by First Light Recovery can call 949-326-3658 or complete a contact form at https://firstlightrecovery.com/contact/ .
  • First Light Recovery generally starts the admissions process with an insurance verification to help potential clients understand what insurance might cover.

LiveToBeHappy, Inc. Announces its Third Acquisition, Adding RenuYou to its Health and Wellness Portfolio

Retrieved on: 
Thursday, November 18, 2021

Neurofeedback is an exciting field in neuro-therapy that is helping people all over the world conquer brain dysregulation issues.

Key Points: 
  • Neurofeedback is an exciting field in neuro-therapy that is helping people all over the world conquer brain dysregulation issues.
  • Dr. Stephanie Christner, a highly acclaimed psychiatrist, will continue to lead RenuYou as its Medical Director.
  • On a trailing twelve-month basis, through September 30, 2021, RenuYou generated over $1.3 million in revenue and over $275 thousand in EBITDA.
  • The Company undertakes no obligation to update or revise any forward-looking statements for any reason, except as required by law.